51 completed, 17 terminated, 12 withdrawn, 6 recruiting. 27 Phase 2, 26 Phase 3, 18 Phase 4, 17 Phase 1, 3 Early Phase 1.
Follow treprostinil: new trials by email Literature Review of treprostinil trials Research Report on treprostinil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose arm - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Not yet recruiting | Liquidia Technologies, Inc. | 75 | 2026-10-26 | 2026-08-07 |
| Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH) Treprostinil, Standard of Care - Pulmonary Hypertension | Early Phase 1 | Recruiting | Valley Health System | 32 | 2026-09-01 | 2026-09-24 |
| A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag LIQ861 (treprostinil) inhalation powder - Pulmonary Arterial Hypertension (PAH) | Phase 4 | Recruiting | Liquidia Technologies, Inc. | 20 | 2026-09-01 | 2026-10-02 |
| TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical Trends treprostinil - Pulmonary Arterial Hypertension (PAH) | Not yet recruiting | AOP Orphan Pharmaceuticals AG | 300 | 2026-07-01 | 2026-07-30 | |
| Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension Treprostinil - Pulmonary Arterial Hypertension (PAH) | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 32 | 2025-10-31 | 2025-09-17 |
| A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin Treprostinil - Pulmonary Arterial Hypertension | Not yet recruiting | Excelsior | 20 | 2025-10-16 | 2025-08-15 | |
| Open Label Treprostinil Raynaud's Study Oral treprostinil (UT-15C) sustained release tablets - Raynaud's Disease, Raynaud Phenomena | Phase 4 | Recruiting | Brigham and Women's Hospital | 30 | 2025-10-15 | 2026-03-24 |
| Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension Inhaled treprostinil - Pulmonary Hypertension | Early Phase 1 | Not yet recruiting | University of California, San Diego | 8 | 2025-10-01 | 2025-08-24 |
| Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer - Progressive Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Recruiting | United Therapeutics | 698 | 2023-10-30 | 2026-07-13 |
| Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin Remunity Pump for Remodulin - Pulmonary Arterial Hypertension | Terminated | United Therapeutics | 9 | 2023-07-05 | 2025-01-16 | |
| Telemonitoring to Treat Group 2 Pulmonary Hypertension Treprostinil Diolamine - Pulmonary Hypertension Due to Left Heart Disease | Phase 2 | Withdrawn | Mardi Gomberg -Maitland MD, MSc | 2023-04-01 | 2023-06-06 | |
| A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy - Pulmonary Arterial Hypertension, Interstitial Lung Disease | Phase 2 | Completed | Mayo Clinic | 29 | 2023-03-13 | 2025-12-03 |
| A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension Parenteral Treprostinil, Oral Treprostinil - Pulmonary Arterial Hypertension | Phase 4 | Active not recruiting | United Therapeutics | 52 | 2022-10-20 | 2025-12-09 |
| Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer - Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Completed | United Therapeutics | 597 | 2022-09-12 | 2026-10-15 |
| Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer - Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Enrolling by invitation | United Therapeutics | 1850 | 2022-09-06 | 2026-10-19 |
| Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone" Control group (ambrisentan plus tadalafil or macitentan plus tadalafil), Treatment group (ambrisentan plus tadalafil plus treprostinil or macitentan plus tadalafil plus treprostinil) - Congenital Heart Disease, Pulmonary Hypertension | Not applicable | Completed | China National Center for Cardiovascular Diseases | 30 | 2022-08-25 | 2026-09-28 |
| A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus Sodium Citrate, Treprostinil, Humalog diluent - Type 1 Diabetes Mellitus | Phase 1 | Completed | Eli Lilly and Company | 40 | 2021-10-22 | 2023-10-04 |
| Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer - Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Completed | United Therapeutics | 598 | 2021-06-01 | 2026-05-05 |
| Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation Treprostinil - Ischemia Reperfusion Injury, Delayed Graft Function | Phase 1 / Phase 2 | Recruiting | Rhode Island Hospital | 20 | 2020-11-13 | 2026-04-23 |
| Implantable System for Remodulin Post-Approval Study Implantable System for Remodulin (treprostinil) - Pulmonary Arterial Hypertension | Withdrawn | Medtronic Cardiac Rhythm and Heart Failure | 2020-08-01 | 2021-07-02 |
Showing 20 of 97. Sign in to see all of them.
Pulmonary Arterial Hypertension (43) · Hypertension, Pulmonary (36) · Lung Diseases, Interstitial (10) · Scleroderma, Systemic (6) · Idiopathic Pulmonary Fibrosis (5) · Chronic Limb-Threatening Ischemia (3) · Emphysema (3) · Heart Defects, Congenital (3) · Peripheral Vascular Diseases (3) · Pulmonary Disease, Chronic Obstructive (3) · Pulmonary Fibrosis (3) · Raynaud Disease (3) · Reperfusion Injury (3) · Scleroderma, Diffuse (3) · Connective Tissue Diseases (2)
United Therapeutics (59) · Stanford University (3) · Brigham and Women's Hospital (2) · Eli Lilly and Company (2) · Liquidia Technologies, Inc. (2) · AOP Orphan Pharmaceuticals AG (1) · Abhinav Humar, MD (1) · Bial - Portela C S.A. (1) · Children's Hospital Medical Center, Cincinnati (1) · China National Center for Cardiovascular Diseases (1) · Excelsior (1) · Ferrer Internacional S.A. (1) · Inova Health Care Services (1) · Insmed Incorporated (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1)
United States (72) · Germany (12) · Canada (11) · France (11) · Israel (10) · Italy (10) · United Kingdom (9) · Australia (8) · Belgium (8) · Netherlands (8) · Austria (7) · China (7) · Mexico (7) · Chile (6) · Poland (6)
Aziz Laurent, MD (4) · Rajan Saggar, MD (4) · Mardi Gomberg-Maitland, MD (3) · James Seibold, MD (2) · Junbo Ge (2) · Kevin Laliberte, PharmD (2) · Aaron B Waxman, MD, PhD (1) · Aaron Waxman, MD, PhD (1) · Aaron Waxman, MD/PhD (1) · Abhinav Humar, M.D. (1) · Ali Ataya, MD (1) · Amadeo Marcos, MD (1) · Ashish Rai Rai, MD (1) · Aziz L Laurent, MD (1)
PMID 41627369, PMID 42776606, PMID 20022264, PMID 20430262, PMID 22628490, PMID 23307827, PMID 23400744, PMID 23597147, PMID 23669822, PMID 24431095, PMID 24603117, PMID 27683610, PMID 28090293, PMID 28090295, PMID 30477763, PMID 31765604, PMID 31858338, PMID 33095030, PMID 33440084, PMID 34214475, PMID 34430604, PMID 34718447, PMID 36115497, PMID 36326260, PMID 37532157, PMID 38055186, PMID 41812190, PMID 42149993, PMID 42548323
2009 (1), 2017 (1)